<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867566</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI301A301</org_study_id>
    <nct_id>NCT02867566</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-na√Øve Patients With Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP&#xD;
      in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2016</start_date>
  <completion_date type="Actual">December 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate(ORR)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission(CR)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival(EFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Diffuse, Large B-Cell, Lymphoma</condition>
  <arm_group>
    <arm_group_label>IBI301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI301 plus CHOP</intervention_name>
    <description>Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.</description>
    <arm_group_label>IBI301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab plus CHOP</intervention_name>
    <description>Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Untreated CD20-positive DLBCL confirmed by histopathology or cytology.&#xD;
&#xD;
          -  18 years to 75 years; Male or female patients.&#xD;
&#xD;
          -  International Prognostic Index (IPI) score of 0 to 2.&#xD;
&#xD;
          -  Signed an informed consent.&#xD;
&#xD;
          -  At least one measurable lesions: for nodal tumor mass, more than 1.5 cm in the long&#xD;
             axis and more than 1.0 cm in the short axis; for extranodal tumor mass, more than 1.0&#xD;
             cm in the long axis.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          -  More than 6 months life expectancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another interventional clinical trial in the past 3 months.&#xD;
&#xD;
          -  Known allergic reactions against monoclonal antibody or rituximab.&#xD;
&#xD;
          -  Contraindication to any component of CHOP regimen.&#xD;
&#xD;
          -  Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial&#xD;
             radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and&#xD;
             surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody&#xD;
             within 3 month.&#xD;
&#xD;
          -  History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for&#xD;
             other disease (e.g., rheumatoid arthritis).&#xD;
&#xD;
          -  Primary central nervous system (CNS) lymphoma, secondary CNS involvement, primary&#xD;
             testicular lymphoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Hospital of Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology; Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

